.png)
Ayutara Therapeutics is a discovery-stage radiopharmaceutical biotechnology company advancing next-generation cancer theranostics through the integrated development of targeted radiopharmaceutical therapies and companion diagnostics.
Ayutara Therapeutics is a discovery-stage radiopharmaceutical biotechnology company developing targeted solutions for precision cancer theranostics, combining therapy with advanced diagnostic insight.
Through innovative ligand engineering, chelator chemistry, and precise radiation delivery, Ayutara works to improve tumor targeting, reduce off-target toxicity, and support scalable clinical development.
Our Story
We design precision alpha and beta radiopharmaceuticals alongside copper-based diagnostic imaging agents to selectively target and destroy cancer cells while minimizing exposure to healthy tissue. Our programs are initially focused on prostate cancer and solid tumors, with platform scalability across multiple oncology indications.
Cutting-edge platforms powering next-generation radiopharmaceuticals
Ayutara integrates advanced computational, chemical, and biological technologies to design, validate, and translate precision radiotheranostics for oncology.
In-silico docking, ADMET modeling, and structure optimization to accelerate ligand discovery and target engagement.
Preclinical SPECT/PET imaging and biodistribution analysis for accurate dose estimation and tumor targeting.
Automated radiolabeling workflows for Actinium-225 and Copper-64 with GMP-aligned protocols.
Leveraging advanced ligand engineering, optimized chelator chemistry, and precision radiation delivery to overcome key limitations of current radiopharmaceuticals.
Ayutara’s platform integrates rational molecular design with alpha and beta radiopharmaceutical payloads to achieve sustained tumor retention and controlled biodistribution.
Our approach addresses tumor targeting, radioactive stability, and clinical scalability across multiple oncology indications.
We pair targeted radiopharmaceutical therapies with copper-based diagnostic imaging agents to enable patient selection, treatment monitoring, and translational precision.
This integrated theranostic strategy aligns scientific innovation with regulatory and clinical requirements.
A focused radiopharmaceutical pipeline advancing targeted oncology programs across discovery, preclinical development, and early clinical readiness.
Indication:Metastatic Castration-Resistant Prostate Cancer (mCRPC) and PSMA-positive solid tumors
Mechanism: PSMA-targeted radiopharmaceutical therapy
ATX-101 is a targeted radiopharmaceutical designed to attach to PSMA-expressing cancer cells. It delivers therapeutic radiation directly to tumors, helping reduce damage to healthy tissue while improving treatment accuracy.
Indication: Pancreatic cancer and other FAP-high solid tumors
Mechanism: FAP-targeted radiopharmaceutical therapy
ATX-202 focuses on tumors with high FAP expression within the tumor environment. The program aims to improve tumor targeting and treatment effectiveness by concentrating therapy where it is needed most.
Indication: Broad solid tumors
Mechanism: Modular radiopharmaceutical platform
ATX-303 is a discovery-stage platform program built to support multiple cancer types. The modular design allows flexibility in therapeutic development, helping expand future treatment options across solid tumors.
Indication: Patient selection and treatment monitoring
Mechanism: PSMA PET diagnostic imaging
ATX-D101 is a diagnostic imaging program used to identify suitable patients and track treatment response. It supports precision care by helping clinicians make informed therapy decisions.
Indication: Patient selection for FAP-targeted therapies
Mechanism: FAP PET diagnostic imaging
ATX-D202 is a diagnostic program designed to detect FAP expression in tumors. It helps guide treatment planning by identifying patients who may benefit from FAP-targeted radiopharmaceutical therapies.
Ayutara is an SEC-compliant, investor-accessible radiopharmaceutical company built under Regulation CF and Regulation A+, enabling broad participation in advancing precision oncology from discovery to clinical impact.